Drug-driven synthetic lethality, fueled by the seminal discovery of PARPi-induced selective cytotoxicity in BRCA1- or BRCA2-deficient cancer cells64,65, represents a paradigm for developing therapeutics by exploiting tumor-specific genetic deficiencies18,54,64–66. Here, BRCA2 is linked to cancer.